Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

出版年份 2021 全文链接

标题

作者

关键词

出版物

Volume 39, Issue 15_suppl, Pages 9503-9503

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2021-06-02

DOI

10.1200/jco.2021.39.15_suppl.9503

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started